Boundless Bio (BOLD) Stock Price, News & Analysis

Company Overview

Boundless Bio, Inc. is a clinical-stage oncology biotechnology company focused on developing medicines for cancers driven by extrachromosomal DNA (ecDNA). These circular DNA structures can amplify cancer-causing genes and contribute to tumor growth, treatment resistance and disease progression. The company’s approach is designed to identify and selectively target vulnerabilities created by ecDNA and oncogene amplification.

Boundless Bio is advancing a pipeline of ecDNA-directed therapeutic candidates, including small-molecule programs intended to interfere with the formation, maintenance or activity of ecDNA-driven oncogenes. Its research and development efforts are focused on precision oncology, with the goal of developing treatments for patients whose tumors contain specific genomic alterations or ecDNA-related features.

Founded in 2018 and headquartered in San Diego, California, Boundless Bio conducts drug discovery and clinical development activities for oncology applications. The company became publicly traded on the Nasdaq under the symbol BOLD in 2024. Boundless Bio is led by President and Chief Executive Officer Zachary M. Hornby.

Key Stats

• Today's Range: $2.39 to $2.69
• 50-Day Range: $2.43 to $3.00
• 52-Week Range: $0.96 to $3.16
• Volume: 463,158 shs
• Average Volume: 161,260 shs
• Market Capitalization: $55.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Boundless Bio Stock Analysis - MarketRank™

Boundless Bio scored higher than 25% of companies evaluated by MarketBeat, and ranked 793rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Boundless Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Boundless Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Boundless Bio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.45% of the float of Boundless Bio has been sold short.

Short Interest Ratio / Days to Cover

Boundless Bio has a short interest ratio ("days to cover") of 4.25.

Change versus previous month

Short interest in Boundless Bio has recently decreased by 4.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Boundless Bio does not currently pay a dividend.

Dividend Growth

Boundless Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Boundless Bio has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Boundless Bio this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $74,185.00 in company stock, which represents 0.1342% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Boundless Bio insiders have bought 136.49% more of their company's stock than they have sold. Specifically, they have bought $128,536.00 in company stock and sold $54,351.00 in company stock.

Percentage Held by Insiders

23.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Boundless Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BOLD
• CIK: 0001782303
• Web: www.boundlessbio.com
• Phone: (858) 766-9912
• Fax: N/A
• Employees: 28
• Year Founded: 2018

Profitability

• EPS (Trailing Twelve Months): ($2.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.89%
• Return on Assets: -47.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.48
• Quick Ratio: 9.48

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.41 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 22,750,000
• Free Float: 17,493,000
• Market Cap: $55.28 million
• Optionable: No Data
• Beta: 0.02